John Wells
Family Medicine · Roosevelt, UTNPI 1831359744
Payments from drug & device makers
Across 157 payments — averaging $17.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$599
- AstraZeneca$345
- Lilly USA, LLC$259
- Zimmer Biomet$182
- Corcept Therapeutics$123
- Novo Nordisk$118
- plus $1K from 25 others
What the payments were for
- Food & beverage$2,720100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 39 | $599 |
| AstraZeneca | 19 | $345 |
| Lilly USA, LLC | 17 | $259 |
| Zimmer Biomet | 2 | $182 |
| Corcept Therapeutics | 7 | $123 |
| Novo Nordisk | 8 | $118 |
| Pfizer | 7 | $107 |
| Astellas Pharma US Inc | 7 | $102 |
| Dexcom, Inc. | 5 | $89 |
| Abbott | 5 | $84 |
| Johnson & Johnson | 4 | $67 |
| Harmony Biosciences LLC | 4 | $65 |
| Medtronic(2 entities) | 4 | $65 |
| Verona Pharma, Inc. | 2 | $61 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $49 |
| Axsome Therapeutics, Inc. | 4 | $48 |
| Boehringer Ingelheim | 2 | $44 |
| Idorsia Pharmaceuticals US Inc | 3 | $40 |
| Xeris Pharmaceuticals, Inc. | 2 | $39 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $35 |
| Jazz Pharmaceuticals Inc. | 1 | $34 |
| Tandem Diabetes Care, Inc. | 2 | $27 |
| Lundbeck LLC | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Vanda Pharmaceuticals Inc. | 1 | $16 |
| GSK | 1 | $16 |
| Agios Pharmaceuticals, Inc. | 1 | $16 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
| Ascensia Diabetes Care US Inc. | 1 | $15 |
| Novartis | 1 | $15 |
| BETA Bionics, Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BioWick X$150
How this compares
$2,720 in reported general payments places this provider in the 75th percentile of 928 family medicine providers in Utah.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 122 | $147,207 |
| EliquisApixaban | 91 | $99,811 |
| OzempicSemaglutide | 81 | $86,459 |
| TrulicityDulaglutide | 83 | $83,069 |
| MounjaroTirzepatide | 61 | $71,497 |
| FarxigaDapagliflozin Propanediol | 47 | $58,824 |
| XareltoRivaroxaban | 43 | $40,701 |
| Xigduo XrDapaglifloz Propaned/Metformin | 15 | $16,533 |
| Tresiba Flextouch U-200Insulin Degludec | 22 | $16,476 |
| JanuviaSitagliptin Phosphate | 19 | $16,266 |
| SynjardyEmpagliflozin/Metformin Hcl | 11 | $16,124 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $12,852 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $9,730 |
| AbilifyAripiprazole | 12 | $8,952 |
| MyrbetriqMirabegron | 12 | $8,336 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy, Synjardy Xr | $44 | $169,834144 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $259 | $156,419159 claims |
| PfizerEliquis | $107 | $99,81191 claims |
| Novo NordiskOzempic | $118 | $86,45981 claims |
| AstraZenecaFarxiga | $345 | $58,82447 claims |
| Johnson & JohnsonXarelto | $67 | $40,70143 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $16 | $24,54351 claims |
| E.r. Squibb & Sons, L.L.C.Abilify | $17 | $8,95212 claims |
| Astellas Pharma US IncMyrbetriq | $102 | $8,33612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 928 family medicine providers in Utah.
Other family medicine in Roosevelt
- John HemmersmeierOgden$24.9M
- Judith KirsteinWest Jordan$22.7M
- Matthew JohnstonSalt Lake City$20.9M
- Jared ProbstSalt Lake City$18.8M
- Bryce PetersonBountiful$16M
- Sarang YoonSalt Lake City$9.4M
- Michael AdamsSandy$8.1M
- Katie JulienSouth Jordan$7.1M
- Scott EricksonBountiful$3.7M
- John RichardsSouth Jordan$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.